Cytokinetics (CYTK) CEO Blum Robert I Sells $472K of Stock

Cytokinetics, Incorporated (CYTK) saw its President and CEO, Robert I. Blum, sell 7,500 shares on October 12, 2026, at a price of $62.88 per share, totaling $471,600. This was a planned transaction, indicating a strategy rather than a reaction to market pressures.

Inside Blum's Trade

Blum sold 7,500 shares, which reflects his ongoing involvement in the company's stock without indicating a lack of confidence. The shares were sold at a price of $62.88 each.

Other Institutional Activity in Cytokinetics

Several institutional investors have also adjusted their stakes in Cytokinetics. Blackrock Inc. increased its holdings by 3,546,259 shares, bringing its total to 20,094,362 shares worth about $1.24 billion. T. Rowe Price Investment Management, Inc. added 1,195,096 shares, resulting in a total of 18,718,498 shares valued at approximately $1.16 billion. Meanwhile, Wellington Management Group, LLP reduced its position by 1,078,133 shares, ending with 6,931,770 shares worth about $429 million. Vanguard Portfolio Management LLC grew its stake by 867,830 shares, totaling 6,711,799 shares valued at around $416 million. State Street Corporation also increased its holdings by 749,158 shares, now holding 6,494,233 shares worth about $402 million.

Cytokinetics, Incorporated Stock Down 2.0%

Cytokinetics shares recently traded around $62.66 as of October 16, 2026. This price is 29% below the stock's 52-week high of $88.31 and 15.4% above its 52-week low of $54.30. The stock is currently trading below its 50-day and 200-day moving averages, which could indicate a bearish trend.

Recent Earnings

Cytokinetics reported trailing twelve-month revenue of $67.67 million, but the company has faced challenges with a year-over-year revenue decline of 57.1%. The next earnings report is scheduled for November 4, 2026.

Insider Buying and Selling at Cytokinetics, Incorporated

In addition to Blum's recent sale, there were several other insider transactions. Fady Ibraham Malik, an officer, sold 3,500 shares at $68.29 each on September 22, 2026, totaling $239,015. Earlier, on September 28, Blum sold another 7,500 shares at $65.46, totaling $490,950. Malik also sold 3,500 shares at $61.38 on October 6, 2026, valued at $214,830.

Analysts Set New Price Targets

Analysts have maintained a strong buy consensus on Cytokinetics. On October 8, 2026, RBC Capital maintained its outperform rating with a target of $113. Earlier, Truist Securities and Barclays also reaffirmed their buy and overweight ratings, respectively, with targets of $112 and $110.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company based in South San Francisco, California, focused on developing treatments for serious diseases by targeting muscle function. The company markets MYQORZO, a small molecule cardiac myosin inhibitor for treating symptomatic oHCM.

Bottom Line

Investors should keep an eye on Cytokinetics as it approaches its next earnings date on November 4, 2026. Blum's recent sale reflects his ongoing strategy in managing his holdings in the company.